Fosamax (Alendronate) Use in Premenopausal Women with Osteoporosis

Evidence-Based Indications for Premenopausal Use

Oral bisphosphonates are recommended as one option for preserving bone density in premenopausal women with treatment-induced menopause, typically secondary to chemotherapy, according to the Journal of Clinical Oncology guidelines 1
Risedronate produced mean BMD differences of 2.5% in lumbar spine and 2.6% in femoral neck at 2 years in women with chemotherapy-induced menopause, with high-quality evidence 1
Clodronate demonstrated preservation of bone density in premenopausal women receiving chemotherapy, with significantly less severe bone loss, particularly in women who developed amenorrhea, based on high-certainty evidence 1
The American College of Physicians guidelines do not specifically address primary osteoporosis in premenopausal women, with all recommendations focusing on postmenopausal women or men, and the evidence is considered low-quality 2, 3

In premenopausal women with normal estrogen levels, tamoxifen may oppose estrogen's effects on bone and potentially increase osteoporosis risk, with moderate-certainty evidence 5
Alendronate should be used in premenopausal women only when chemotherapy or cancer treatment has induced premature menopause, with high-quality evidence 1
The woman should have documented osteoporosis with significant fracture risk, based on moderate-certainty evidence 2

Treat for 5 years initially, with high-certainty evidence, and do not monitor BMD during the 5-year treatment period, as BMD changes do not predict fracture benefit, according to the Annals of Internal Medicine guidelines 2, 4
No difference in serious adverse events compared to placebo in high-certainty evidence, and mild upper GI symptoms are most common, with moderate-certainty evidence 4
Osteonecrosis of the jaw occurs in 0.01-0.3% of users, with risk increasing with longer duration, based on low-quality evidence 4